WebMar 16, 2024 · Recent published studies have raised the possibility of targeted radionuclide therapies such as 177Lutetium‐PSMA (prostate‐specific membrane antigen) as a viable therapeutic option in men with metastatic prostate cancer.1, 2, 3, 4, 5, 6, 7, 8, 9, 10The aim of this review was to discuss practical aspects of Lu PSMA therapy including, … WebApr 12, 2024 · Emmanuel Antonarakis joins Alicia Morgans in a conversation about the trial in progress multicenter, open-label, randomized phase 3 ECLIPSE trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus standard-of-care hormone therapy in patients with metastatic castration-resistant prostate cancer, previously treated with only one ARAT …
Cancers Free Full-Text PSMA PET Imaging and Therapy in …
WebSince 2013, 131I-related PSMA therapy has been replaced by 177Lu-labeled ligands, such as PSMA-617, which is also the subject of multicenter studies. Alternative PSMA ligands for both imaging and therapy are available. Among them is 99mTc-MIP-1404, which has recently entered a phase 3 clinical trial. WebAug 20, 2024 · PSMA has been a topic of interest during the past decade for both diagnostic and therapeutic targets. Radioligand therapy (RLT) utilizes the delivery of radioactive nuclides to tumors and tumor-associated targets, and it has shown better efficacy with minimal toxicity compared to other systemic cancer therapies. gluten free cakes phoenix
PSMA ligands in prostate cancer - ScienceDirect
WebDec 27, 2024 · The aim of this work was to investigate the effect of ligand amount, affinity and internalization of prostate-specific membrane antigen (PSMA)-specific ligands on the activity concentrations... Webagents. Especially given the high level of safety of 177Lu-PSMA radio-ligand therapy, with only minimal grade 3 and 4 toxicities reported so far, it has the potential to expand options for metastatic castration-resistant PC. This review is intended to provide a comprehensive over-view of the current literature on low-molecular-weight PSMA ligands WebMar 1, 2024 · We analyzed real-world clinical outcomes of sequential α-/β-emitter therapy for metastatic castration-resistant prostate cancer (mCRPC). Methods: We assessed safety and overall survival in 26 patients who received 177Lu-prostate-specific membrane antigen ligand (177Lu-PSMA) after 223Ra in the ongoing noninterventional REASSURE study … boland application status